COMPARATIVE IMMUNOGENICITY OF CONJUGATES COMPOSED OF ESCHERICHIA-COLI O111 O-SPECIFIC POLYSACCHARIDE, PREPARED BY TREATMENT WITH ACETIC-ACID OR HYDRAZINE, BOUND TO TETANUS TOXOID BY 2 SYNTHETIC SCHEMES

被引:30
作者
GUPTA, RK
EGAN, W
BRYLA, DA
ROBBINS, JB
SZU, SC
机构
[1] NICHHD,BETHESDA,MD 20892
[2] US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892
关键词
D O I
10.1128/IAI.63.8.2805-2810.1995
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Escherichia coli O111, of various H types and virulence factors, causes enteritis throughout the world, especially in young children. This O type is found rarely in healthy individuals. Serum antibodies to the O-specific polysaccharide of O111 lipopolysaccharide (LPS) protect mice and dogs against infection with this E. coli serotype. The O111 O-specific polysaccharide is composed of a pentasaccharide repeat unit with two colitoses bound to the C-3 and C-6 of glucose in a trisaccharide backbone; this structure is identical to that of Salmonella adelaide (O35), another enteric pathogen. Nonpyrogenic O111 O-specific polysaccharide was prepared by treatment of its LPS with acetic acid (O-SP) or the organic base hydrazine (DeA-LPS). The O-SP had a reduced concentration of colitose. These products were derivatized with adipic acid dihydrazide (ADH) or thiolated with N-succinimidyl-3(2-pyridyldithio) propionate (SPDP). The four derivatives were covalently bound to tetanus toroid (TT) by carbodiimide-mediated condensation or with SPDP to form conjugates. Immunization of BALB/c and general-purpose mice by a clinically acceptable route showed that DeA-LPST-TTADH, of the four conjugates, elicited the highest level of LPS antibodies. Possible reasons to explain this differential immunogenicity between the four conjugates are discussed.
引用
收藏
页码:2805 / 2810
页数:6
相关论文
共 52 条
[31]  
NETER E, 1953, PEDIATRICS, V12, P377
[32]  
NETER E, 1955, PEDIATRICS, V16, P601
[33]   ANTIBACTERIAL AND PROTECTIVE PROPERTIES OF MONOCLONAL-ANTIBODIES REACTIVE WITH ESCHERICHIA-COLI O111-B4 LIPOPOLYSACCHARIDE - RELATION TO ANTIBODY ISOTYPE AND COMPLEMENT-FIXING ACTIVITY [J].
OISHI, K ;
KOLES, NL ;
GUELDE, G ;
POLLACK, M .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :34-45
[34]  
OLARTE J, 1952, J LAB CLIN MED, V40, P252
[35]   ESCHERICHIA-COLI SEROTYPING AND DISEASE IN MAN AND ANIMALS [J].
ORSKOV, F ;
ORSKOV, I .
CANADIAN JOURNAL OF MICROBIOLOGY, 1992, 38 (07) :699-704
[36]  
PEETERS CCAM, 1991, J IMMUNOL, V146, P4308
[37]   ANTIBODIES TO O-ANTIGEN OF LIPOPOLYSACCHARIDE ARE PROTECTIVE AGAINST NEONATAL INFECTION WITH ESCHERICHIA-COLI K1 [J].
PLUSCHKE, G ;
ACHTMAN, M .
INFECTION AND IMMUNITY, 1985, 49 (02) :365-370
[38]   COMPARISON OF CONJUGATES COMPOSED OF LIPOPOLYSACCHARIDE FROM SHIGELLA-FLEXNERI TYPE-2A DETOXIFIED BY 2 METHODS AND BOUND TO TETANUS TOXOID [J].
POLOTSKY, VY ;
ROBBINS, JB ;
BRYLA, D ;
SCHNEERSON, R .
INFECTION AND IMMUNITY, 1994, 62 (01) :210-214
[39]   EPIDEMIOLOGIC SURVEY OF THE ENTEROPATHOGENIC ESCHERICHIA-COLI ISOLATED FROM CHILDREN WITH DIARRHEA [J].
REGUA, AH ;
BRAVO, VLR ;
LEAL, MC ;
LEITE, MELL .
JOURNAL OF TROPICAL PEDIATRICS, 1990, 36 (04) :176-179
[40]   HYPOTHESIS FOR VACCINE DEVELOPMENT - PROTECTIVE IMMUNITY TO ENTERIC DISEASES CAUSED BY NONTYPHOIDAL SALMONELLAE AND SHIGELLAE MAY BE CONFERRED BY SERUM IGG ANTIBODIES TO THE O-SPECIFIC POLYSACCHARIDE OF THEIR LIPOPOLYSACCHARIDES [J].
ROBBINS, JB ;
CHU, CY ;
SCHNEERSON, R .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (02) :346-361